ESMO 2021 | KEYNOTE 826: pembrolizumab + chemo in patients with advanced cervical cancer

Isabelle Ray-Coquard, MD, PhD, of the Léon Bérard Center and the Claude Bernard University Lyon 1, Lyon, France, discusses the KEYNOTE-826 trial (NCT03635567), a Phase III study assessing the efficacy and safety of pembrolizumab plus one of four platinum-based chemotherapy regimens compared to the efficacy and safety of placebo plus one of four platinum-based chemotherapy regimens in the treatment of adult women with persistent, recurrent, or metastatic cervical cancer. This interview took place during the European Society for Medical Oncology (ESMO) 2021 congress.